68399-12-2

Usage

Uses

Used in Pharmaceutical Industry:
(2E,5E)-7-[(1R)-2β-[(E,R)-4-(3-Chlorophenoxy)-3-hydroxy-1-butenyl]-3α,5α-dihydroxycyclopentan-1α-yl]-2,5-heptadienoic acid methyl ester is used as a potential pharmaceutical compound for its possible biological activity and reactivity due to its unique chemical structure and functional groups.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, (2E,5E)-7-[(1R)-2β-[(E,R)-4-(3-Chlorophenoxy)-3-hydroxy-1-butenyl]-3α,5α-dihydroxycyclopentan-1α-yl]-2,5-heptadienoic acid methyl ester serves as a subject of study for its potential to interact with biological targets, given its complex structure and the presence of multiple chiral centers, which may offer selectivity in binding and activity.
Used in Chemical Synthesis:
(2E,5E)-7-[(1R)-2β-[(E,R)-4-(3-Chlorophenoxy)-3-hydroxy-1-butenyl]-3α,5α-dihydroxycyclopentan-1α-yl]-2,5-heptadienoic acid methyl ester is utilized as a synthetic target for chemical synthesis, allowing researchers to explore new methods and pathways for creating complex organic molecules with potential applications in various fields.
Used in Drug Discovery:
As a part of drug discovery efforts, (2E,5E)-7-[(1R)-2β-[(E,R)-4-(3-Chlorophenoxy)-3-hydroxy-1-butenyl]-3α,5α-dihydroxycyclopentan-1α-yl]-2,5-heptadienoic acid methyl ester is investigated for its potential as a lead molecule. Its unique structural features and the presence of a cyclopentane ring with hydroxyl groups and a chlorophenyl side chain may provide a foundation for the development of new drugs with specific therapeutic effects.

InChI:InChI=1/C23H29ClO6/c1-29-23(28)10-5-3-2-4-9-19-20(22(27)14-21(19)26)12-11-17(25)15-30-18-8-6-7-16(24)13-18/h2,4-8,10-13,17,19-22,25-27H,3,9,14-15H2,1H3/b4-2+,10-5+,12-11+/t17-,19?,20-,21?,22?/m1/s1

Upstream product

• 69222-86-2 (2E,5E)-7-[(1R,2R,3R,5S)-2-[(E)-(R)-4-(3-Chloro-phenoxy)-3-(tetrahydro-pyran-2-yloxy)-but-1-enyl]-3,5-bis-(tetrahydro-pyran-2-yloxy)-cyclopentyl]-hepta-2,5-dienoic acid methyl ester 
• 56687-85-5 methyl (8R,9S,11R,12S,15S)-16-(m-chlorophenoxy)-9,11,15-trihydroxy-17,18,19,20-tetranor-5Z,13E-prostadienoate 
• 69222-88-4 16-(3-chlorophenoxy)-17,18,19,20-tetranor-5,6-trans-didehydroprostaglandin F_1α methyl ester 9,11,15-tris(tetrahydropyran-2-yl ether) 
• 62559-75-5 (E)-7-[(1R,2R,3R,5S)-2-[(E)-(R)-4-(3-Chloro-phenoxy)-3-(tetrahydro-pyran-2-yloxy)-but-1-enyl]-3,5-bis-(tetrahydro-pyran-2-yloxy)-cyclopentyl]-2-phenylselanyl-hept-5-enoic acid methyl ester 
• 69222-87-3 16-(3-chlorophenoxy)-17,18,19,20-tetranor-5,6-trans-didehydroprostaglandin F_1α methyl ester 

Relevant academic research and scientific papers

Prostaglandin Analogues Possessing Antinidatory Effects. 2. Modification of the α Chain

Additional double bonds were introduced into the α chain in 16-phenoxy-, 16-(3-chlorophenoxy)-, 16--, and 16-(4-chlorophenoxy)-17,18,19,20-tetranorprostaglandins which have antinidatory effects.Of these analogues, the Δ3/